Literature DB >> 3687892

Two new rating scales for opiate withdrawal.

L Handelsman1, K J Cochrane, M J Aronson, R Ness, K J Rubinstein, P D Kanof.   

Abstract

Two new rating scales for measuring the signs and symptoms of opiate withdrawal are presented. The Subjective Opiate Withdrawal Scale (SOWS) contains 16 symptoms whose intensity the patient rates on a scale of 0 (not at all) to 4 (extremely). The Objective Opiate Withdrawal Scale (OOWS) contains 13 physically observable signs, rated present or absent, based on a timed period of observation of the patient by a rater. Opiate abusers admitted to a detoxification ward had significantly higher scores on the SOWS and OOWS before receiving methadone as compared to after receiving methadone for 2 days. Opiate abusers seeking treatment were challenged either with placebo or with 0.4 mg naloxone. Postchallenge SOWS and OOWS scores were significantly higher than prechallenge scores in the naloxone but not the placebo group. We have demonstrated good interrater reliability for the OOWS and good intrasubject reliability over time for both scales in controls and in patients on a methadone maintenance program. These scales are demonstrated to be valid and reliable indicators of the severity of the opiate withdrawal syndrome over a wide range of common signs and symptoms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3687892     DOI: 10.3109/00952998709001515

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  157 in total

1.  Problem drinking and low-dose naltrexone-assisted opioid detoxification.

Authors:  Paolo Mannelli; Kathleen Peindl; Ashwin A Patkar; Li-Tzy Wu; Haresh M Tharwani; David A Gorelick
Journal:  J Stud Alcohol Drugs       Date:  2011-05       Impact factor: 2.582

2.  Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms.

Authors:  Jermaine D Jones; Rachel R Luba; Jonathan L Vogelman; Sandra D Comer
Journal:  Am J Addict       Date:  2015-12-21

3.  The impact of naturalistic cannabis use on self-reported opioid withdrawal.

Authors:  Cecilia L Bergeria; Andrew S Huhn; Kelly E Dunn
Journal:  J Subst Abuse Treat       Date:  2020-03-30

4.  Validity and reliability of the DDS for severity of delirium in the ICU.

Authors:  Hilke Otter; Jörg Martin; Katrin Bäsell; Christian von Heymann; Ortrud Vargas Hein; Patricia Böllert; Pattariya Jänsch; Ina Behnisch; Klaus-Dieter Wernecke; Wolfgang Konertz; Stefan Loening; Jens-Uwe Blohmer; Claudia Spies
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

5.  Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Authors:  Maria A Sullivan; Suzanne K Vosburg; Sandra D Comer
Journal:  Psychopharmacology (Berl)       Date:  2006-09-14       Impact factor: 4.530

6.  Ondansetron Does Not Reduce Withdrawal in Patients With Physical Dependence on Chronic Opioid Therapy.

Authors:  Larry F Chu; John Sun; Anna Clemenson; Matthew J Erlendson; Tom Rico; Erika Cornell; Hannah Obasi; Zahra N Sayyid; Ellen M Encisco; Jeff Yu; Jamison G Gamble; Ian Carroll; J David Clark
Journal:  J Addict Med       Date:  2017 Sep/Oct       Impact factor: 3.702

7.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

8.  Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.

Authors:  Jennifer R Schroeder; Karran A Phillips; David H Epstein; Michelle L Jobes; Melody A Furnari; Ashley P Kennedy; Markus Heilig; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2018-08-06       Impact factor: 4.530

9.  Reduced cold pain tolerance in chronic pain patients following opioid detoxification.

Authors:  Jarred Younger; Peter Barelka; Ian Carroll; Kim Kaplan; Larry Chu; Ravi Prasad; Ray Gaeta; Sean Mackey
Journal:  Pain Med       Date:  2008-06-18       Impact factor: 3.750

Review 10.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.